No matches
Rhinology

ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP

Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.
Vibeke Backer
DMSc, MD
Vibeke Backer

Related resources

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

expert video
ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

expert video
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

expert video
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients

Podcast
ADVENT On Air | Remission in CRSwNP

ADVENT On Air | Remission in CRSwNP

Podcast
EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

expert video
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

expert video
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

expert video
Connecting Type 2 Inflammation to CRSwNP

Connecting Type 2 Inflammation to CRSwNP

expert video
CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

interactivity
IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video
IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

expert video
IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

expert video
IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

expert video
CRSwNP: A Chronic Type 2 Inflammatory Disease

CRSwNP: A Chronic Type 2 Inflammatory Disease

expert video

Description

Prof. Backer will expertly navigate the intricate relationship between Type 2 inflammation and the most challenging forms of CRSwNP. This presentation will move beyond symptomatic management to explore the fundamental immunological pathways that contribute to disease severity and disease relapse.

Tags
disease controlCRSwNPpatient burdendisease severityacute exacerbations
MAT-GLB-2504853 - 1.0 - 09/2025

About this expert

Pulmonology

Vibeke Backer

DMSc, MD

Chief Respiratory Physician, Department of ENT and Centre for Physical Activity Research | Rigshospitalet, Copenhagen, Denmark

See author’s profile
Vibeke Backer

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region